IGC Pharma Inc. announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,465,589, titled "Methods and Composition for Treating CNS Disorders." The patent covers the proprietary formulation used in IGC-AD1, which is being evaluated in a Phase 2 trial for agitation in Alzheimer's disease. The composition is designed to address Alzheimer's-related amyloid plaque and tau tangles, as well as symptoms such as agitation, memory issues, anxiety, and sleep disturbances. The approach targets both behavioral symptoms and underlying disease mechanisms, aiming to deliver safer and more effective treatment options for patients.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1101897) on November 13, 2025, and is solely responsible for the information contained therein.